Baker Hughes Company (BKR) Is 'So Smart,' Says Jim Cramer
Baker Hughes Company (NASDAQ:BKR) is an oil and gas production equipment company that has managed to perform better on the stock market when compared to rivals and peers SLB and Halliburton. The stock has gained 9.6% year-to-date on the back of a 16% gain in July due to the firm's latest EPS and revenue beating analyst estimates. Cramer's previous comments about Baker Hughes Company (NASDAQ:BKR) have pointed to the strong performance, and this time, he discussed the specifics of the strong performance:
'[$13.6 billion deal to buy Chart] Oh my god, that deal is so smart, particularly in light of liquefied natural gas. They've always had the great equipment. They've also had, remember they used to have the [inaudible]. They had the welders. You need a lot of welders. That's a great deal.
Copyright: Elnur / 123RF Stock Photo
Here are Cramer's previous remarks about Baker Hughes Company (NASDAQ:BKR):
'But not as many as you would think. I mean, look, oil and gas, you would think that would be terrible with oil in the 60s, they're doing pretty well. Well, Schlumberger and Haliburton have a hard time. Baker Hughes actually had a good quarter. But then, out of nowhere, you get this LNG deal. And you say, wow, I mean there's an industry that's got customers for the rest of its duration.'
While we acknowledge the potential of BKR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
OrthoPediatrics Corp. to Participate in the 45th Canaccord Genuity Annual Growth Conference
WARSAW, Ind., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ('OrthoPediatrics' or the 'Company') (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 45th Canaccord Genuity Annual Growth Conference, held in Boston, MA. Event: 45th Canaccord Genuity Annual Growth Conference Format: Fireside ChatDate: Wednesday, August 13, 2025Time: 11:00 am ET An audio webcast of the discussion will be available online at the OrthoPediatrics' investor relations website, Additionally, a replay will be available after the event. About OrthoPediatrics in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics' global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit Investor Contact Philip Trip Taylor Gilmartin Groupphilip@ in to access your portfolio
Yahoo
a minute ago
- Yahoo
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025
PLYMOUTH MEETING, Pa., Aug. 4, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter 2025 financial results will be released after the market close on August 12, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available online at This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event. About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit ContactsMedia: Jennie Willson, (267) 429-8567, communications@ Peter Vozzo - ICR Healthcare, (443) 213-0505, View original content to download multimedia: SOURCE INOVIO Pharmaceuticals, Inc.
Yahoo
a minute ago
- Yahoo
FibroGen to Report Second Quarter 2025 Financial Results
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on FibroGen's website. About FibroGenFibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit For Investor Inquiries:David DeLucia, CFASenior Vice President and Chief Financial Officerir@
